FINDMED (https://findmed.fr), through its series of webinars, introduces you to some of the best expertise and technological platforms of the Carnot Institutes of our consortium, which are accessible to companies in the fields of drugs and health technologies. Note that this second webinar will also be the opportunity to involve a CRO, the company PopsiCube, which is also a member of the AFSSI.
We propose to evoke the main expertises and technologies concerning the synthesis of biomolecules and biopolymers, the intestinal microbiota at the service of health, and clinical research through the agile and digital approach of the company PopsiCube. Expertise that may be of interest to VSEs, SMEs and ETIs.
This webinar will be led by Professor Gilles Subra, Head of the Peptides Plateau of the Synbio3 platform at Carnot Chimie Balard Cirimat, Philippe Langella, Head of the laboratory of interactions of commensal and probiotic bacteria with the host at the Institut Micalis of INRA and Carnot Qualiment, and Claudine Richon, export project manager for the company PopsiCube.
Design and synthesis of biomolecules
Analysis of bioactive molecules : peptides, pseudopeptides and heterocycles
Synthesis of labelled molecules for pharmacological studies or imaging
Bioconjugated peptides for vectorization and targeting
The effects of microorganisms on health
interactions Intestinal bacteria and the treatment of pathologies
Innovations in clinical research Agile and digital
approach for the capture and management of health
data Specific tailor-made solutions for randomization, data capture and management
Participation in this webinar is free but subject to registration.
Findmed is a consortium of 10 Carnot institutes, which are French academic research institutions dedicated to setting up collaborative research partnerships with the private sector. industry (from SMEs to international corporations). The objective of Findmed is to facilitate the access of private companies to their expertise and technological resources, so as to contribute to the reinforcement of the medication / drug discovery sector in France.